Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin)

Journal of the American Chemical Society

Volumn 125, Issue 32, 2003, Pages 9740-9749

  Baba, Yoshiyasu ^a,b,c   Hirukawa, Nozomu ^a,b   Tanohira, Naoto ^b   Sodeoka, Mikiko ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b SAGAMI CHEMICAL RESEARCH CENTER   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTRACELLULAR SIGNAL TRANSDUCTIONS;

BINDING ENERGY; CATALYSIS; CELLS; MOLECULAR STRUCTURE; PROTEINS;

ENZYME INHIBITION;

1 ACETOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; 1 BENZOYLOXYMETHYL 5 (4 PHENYLBUTANOYLOXYMETHYL) 7 OXABICYCLO[2.2.1]HEPT 5 ENE 2,3 DICARBOXYLIC ANHYDRIDE; 1 BENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; 1,5 DIBENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPT 5 ENE 2,3 DICARBOXYLIC ANHYDRIDE; 1,5 DIBENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; 1,6 DIBENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPT 5 ENE 2,3 DICARBOXYLIC ANHYDRIDE; 1,6 DIBENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; 2 BENZOYLOXYMETHYL 3 (4 PHENYLBUTANOYLOXYMETHYL)FURAN; 2 BENZOYLOXYMETHYL 4 (4 PHENYLBUTANOYLOXYMETHYL)FURAN; 2 HYDROXYMETHYL 3 (4 PHENYLBUTANOYLOXYMETHYL)FURAN; 2 HYDROXYMETHYL 4 (4 PHENYLBUTANOYLOXYMETHYL)FURAN; 2,3 BIS(BENZOYLOXYMETHYL)FURAN; 2,4 BIS(BENZOYLOXYMETHYL)FURAN; 3 BENZOYLOXYMETHYL 2 HYDROXYMETHYLFURAN; 3 FURYLMETHYL 4 PHENYLBUTANOATE; 3 FURYLMETHYLBENZOATE; 4 BENZOYLOXYMETHYL 2 HYDROXYMETHYLFURAN; 5 ACETOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; 5 BENZOYLOXYMETHYL 7 OXABICYCLO[2.2.1]HEPTANE 2,3 DICARBOXYLIC ANHYDRIDE; ACID ANHYDRIDE; BENZOIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; CANTHARIDIN; CYCLOSPORIN A; FURAN DERIVATIVE; IMMUNOPHILIN; NORCANTHARIDIN; PROTEIN SERINE THREONINE KINASE; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CATALYSIS; CELL PROLIFERATION; DRUG SYNTHESIS; ENZYME INHIBITION; MATHEMATICAL COMPUTING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

BINDING SITES; CALCINEURIN; CANTHARIDIN; CATALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0041624233     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja034694y     Document Type: Article

References (36)

1. (a) Hunter, T. Cell 1995, 80, 225-236.
2. (b) Taylor, W. P.; Widlanski T. S. Chem. Biol. 1995, 2, 713-718.
3. (c) Cohen, P.; Cohen, P. T.,I. J. Biol. Chem. 1989, 264, 21435-21438.
4. (d) Cohen, P. Annu. Rev. Biochem 1989. 58, 453-508.
5. Klee, C. B.: Draetta, G. F.; Hubbard, M. J. Adv. Enzymol Relat. Areas Mol. Biol. 1988, 61, 149-200.
6. (a) Takai, A.; Bialojan, C.; Troschka, M.; Rüegg J. C. FEBS Lett. 1987, 217, 81-84.
7. (b) MacKintosh, C.; Klumpp, S. FEBS Lett. 1990, 277. 137-140.
8. (c) MacKintosh C.; Beattie, K. A.; Klumpp, S.; Cohen, P.; Codd, G. A. FEBS Lett. 1990, 264, 187-192.
9. (a) Liu. J.; Farmer. J. D., Jr.: Lane W. S.; Friedman, J.; Weissman, I.: Schreiber, S. L. Cell 1991, 66. 807-815.
10. (b) Schreiber, S. L.; Albers, M. W.; Brown. E. J. Acc. Chem Res. 1993, 26. 412-420 and references cited therein.
11. Andreeva, L.; Heads, R.; Green, C. J. Int. J. Exp. Pathol 1999, 80, 305-315.
12. Approaches for increasing affinity to a target protein by tethering two individual fragments have already been successfully demonstrated. See: (a) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Science 1996, 274, 1531-1534. Mammen M.; Choi, S.-K.; Whitesides, G. M. Angew. Chem., Int. Ed. 1998, 37, 2754-2794 and references therein.
13. Approaches for increasing affinity to a target protein by tethering two individual fragments have already been successfully demonstrated. See: (a) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Science 1996, 274, 1531-1534. Mammen M.; Choi, S.-K.; Whitesides, G. M. Angew. Chem., Int. Ed. 1998, 37, 2754-2794 and references therein.
14. (a) Sodeoka M.; Sampe R.; Kojima, S.; Baba, Y.; Usui, T.; Ueda, K.; Osada, H. J. Med. Chem, 2001, 44, 3216-3222.
15. (b) Usui, T.; Kojima, S.; Kidokoro, S.; Ueda, K.; Osada, H.; Sodeoka M. Chem. Biol. 2001, 8, 1209-1220.
16. (c) Sodeoka M.: Baba. Y. Yuki Gosei Kagaku Kyokaishi 2001, 59, 1095-1102.
17. Goldberg, J.; Huang, H. B.; Kwon, Y. G.; Greengard, P.; Nairn,; A. C.; Kuriyan, J. Nature 1995, 376, 745-753. Recently, the crystal structure of the PP1 - calyculin complex was also reported. See: Kita, A.; Matsunaga S.; Takai, A.; Kataiwa, H.; Wakimoto T.; Fusetani, N.; Isobe, M.; Miki, K. Structure 2002, 10, 715-724.
18. Goldberg, J.; Huang, H. B.; Kwon, Y. G.; Greengard, P.; Nairn,; A. C.; Kuriyan, J. Nature 1995, 376, 745-753. Recently, the crystal structure of the PP1 - calyculin complex was also reported. See: Kita, A.; Matsunaga S.; Takai, A.; Kataiwa, H.; Wakimoto T.; Fusetani, N.; Isobe, M.; Miki, K. Structure 2002, 10, 715-724.
19. (a) Kissinger, C. R.; Perge, H. E.; Knighton, D. R.; Lewis, C. T.; Pelletier, L. A.; Tempczyk, A.; Kalish, V. J.; Tucker, K. D.; Showalter, R. E.; Moomaw, E. W.; Gastinel. L. N.; Habuka, N.; Chen, X.; Maldonado, F,; Barker, J. E.; Bacquet, R.; Villafranca J. E. Nature 1995. 378, 641.
20. (b) Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thomson, J. A.; Fitzgibbon, M. J.; Fleming, M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A. Cell 1995, 82, 507-522.
21. Sheppeck, J. E.; Gauss, C,-M.; Chamberlin, A. R. Bioorg. Med. Chem. 1997, 5, 1739-1750 and references therein.
22. (a) Li, Y.-M.; Casida, J. E. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11867-11870.
23. (b) Li, Y.-M.; MacKintosh, C.; Casida, J. E. Biochem. Pharmacol. 1993, 46, 1435-1443.
24. (c) Honkanen, R. E. FEBS Lett. 1993, 330, 283-286 and references therein.
25. (a) McCluskey A.; Taylor, C.; Quinn, R. J. Bioorg. Med. Chem. Lett. 1996, 6, 1025-1028.
26. (b) Enz, A.; Zenke, G.; Pombo-Villar. E. Bioorg. Med. Chem. Lett. 1997, 7, 2513-2518.
27. (c) McCluskey, A.; Keane, M. A.; Mudgee, L.-M.; Sim, A. T. R.; Sakoff, J.; Quinn, R. J. Eur. J. Med. Chem. 2000, 35, 957-964.
28. (d) McCluskey A.; Bowyer, M. C.; Collins, E.; Sim, A. T. R.; Sakoff, J. A.; Baldwin, M. L. Bioorg. Med. Chem. Lett. 2000, 10, 1687-1690.
29. (e) McCluskey, A.; Walkom, C.; Bowyer, M. C.; Ackland, S. P.; Gardiner, E.; Sakoff, J. A. Bioorg. Med. Chem. Lett. 2001, 11, 2941-2946.
30. (f) McCluskey, A.; Keane, M. A.; Walkom, C. C.; Bowyer, M. C.; Sim, A. T. R.; Young, D. J.; Sakoff, J. A. Bioorg. Med. Chem. Lett. 2002. 12, 391 -393,
31. Preliminary SAR results have already been reported; see: Sodeoka, M.; Baba, Y.; Kobayashi, S.; Hirukawa, N. Bioorg. Med. Chem. Lett. 1997, 7, 1833-1836.
32. Matsuzawa, M.; Graziano, M. J.; Casida, J. E. J. Agric. Food Chem. 1987, 35, 823-829.
33. Increased inhibition of PP2B by 1 and 2 has also been reported; see ref 11c.
34. Sugiyama, Y.; Ohtani, I. I.; Isobe, M.; Takai, A.; Ubukata, M.; Isono, K. Bioorg. Med. Chem. Lett. 1996, 6, 3-8.
35. Tatlock et al. also reported that substitution of the 5-endo-hydrogen of norcantharidin by hydrophobic residues increased inhibition of PP2B; see: Tatlock, J. H.; Linton, M. A.; Hou, X. J.; Kissinger, C. R.; Pelletier, L. A.; Showalter, R. E.; Tempczyk, A.; Villafranca, J. E. Bioorg. Med. Chem. Lett. 1997, 7, 1007-1012.
36. Swanson, S. K.-H.; Born, T.: Zydowsky, L. D.; Cho, H.; Chang, H. Y.; Walsh. C.; Rusnak, F. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3741-3745.